ReviewBMJ (Clinical research ed.)2007
How can we regulate medicines better?
Review in BMJ (Clinical research ed.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer.European journal of clinical pharmacology · 2024Trial
- Assessing the credibility of a drug's effects: identification and judgment of uncertainty by the Dutch Medicines Evaluation Board.Frontiers in medicine · 2024Article
- National pharmacy associations in the commonwealth: current scenario and future needs to maximise effective contributions of the pharmacy profession towards universal health coverage.Journal of pharmaceutical policy and practice · 2021Article
- HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?Journal of the Royal Society of Medicine · 2020Article
- Less Is More: Norwegian Drug Regulation, Antibiotic Policy, and the "Need Clause".The Milbank quarterly · 2019Article
- Patients not patents: Drug research and development as a public enterprise.European journal of clinical investigation · 2018Article
- Article
- Functional evaluation and practice survey to guide purchasing of intravenous cannulae.BMC anesthesiology · 2013Article
- Article
- Does the development of new medicinal products in the European Union address global and regional health concerns?Population health metrics · 2010Article
- Risk Management Plans: are they a tool for improving drug safety?European journal of clinical pharmacology · 2010Article
- Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.BMC health services research · 2010Review
- Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.Nature reviews. Drug discovery · 2010Review
- The Italian Horizon Scanning Project.European journal of clinical pharmacology · 2009Article
- A New Vaccine for Tuberculosis: The Challenges of Development and Deployment.Journal of bioethical inquiry · 2009Article
- Enhancing the rational use of new medicines across European health care systems.European journal of clinical pharmacology · 2008Article
- Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.PharmacoEconomics · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.